PDX Pharmaceuticals Inc.
Portland, OR
- UEI
- VTX7JRKLC3F5
- CAGE
- 66ST6
- Primary NAICS
- 541713 Research and Development in Nanotechnology
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 3303 S Bond Ave, Portland, OR 97239, USA
- Website
- pdxpharm.com
- Founded
- 2010
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Novel sirna-nanoparticle platform for treating drug-resistant HER2 positive breast cancer | National Cancer Institute (NIH) | $1,200,000 |
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Senex Biotechnology Inc. | Maynard, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Athna Biotech Inc. | Watkinsville, GA | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Nanocan Therapeutics Corporation | Forest Heights, MD | 541713 Research and Development in Nanotechnology |
| Biopharmaceutical | Atlanta, GA | 621511 Medical Laboratories |
| Leukogene Therapeutics Inc. | Mount Pleasant, SC | — |
About the company
PDX Pharmaceuticals Inc. is a biotechnology company registered in SAM.gov since 2010, specializing in developing innovative nanoparticle-based immunotherapies for cancer treatment. The company is a minority-owned, woman-owned business focused on advanced pharmaceutical research and development, with a particular emphasis on creating novel therapeutic approaches for challenging cancer types. Their core expertise lies in nanotechnology and cancer systems biology, enabling them to design sophisticated drug delivery platforms that maximize treatment efficacy while minimizing toxicity.
The company has secured multiple federal grants from the National Cancer Institute, specifically focused on developing advanced immunotherapies for non-small cell lung cancer (NSCLC). Their primary research initiatives include developing nanoconstructs like ARAC-02 and PETTRA, which utilize sophisticated nanoparticle platforms to co-deliver multiple therapeutic agents such as siRNA, antibodies, and immune stimulants. These grants, ranging from $321,304 to unspecified amounts, support research aims like pursuing international patent protection, initiating GMP-compliant manufacturing, optimizing nanoparticle constructs, and conducting preclinical efficacy and safety evaluations. PDX Pharmaceuticals has partnered with research institutions like Oregon Health and Science University, and leverages advanced techniques like in situ tumor vaccination and targeted drug delivery to potentially improve cancer treatment outcomes, particularly for patients resistant to current immunotherapy approaches.
Quick answers
Is PDX Pharmaceuticals Inc. registered in SAM.gov?
Yes. PDX Pharmaceuticals Inc.'s SAM.gov registration is active through September 15, 2027.
What is PDX Pharmaceuticals Inc.'s most recent federal award?
PDX Pharmaceuticals Inc.'s most recent federal grant award is Advancing the commercialization readiness of nanoparticle-based immunotherapy for cancer treatment - treatment of… (SB1CA287735), from National Cancer Institute (NIH), on September 5, 2024.
On GovTribe
See PDX Pharmaceuticals Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors